Skip to main content

Table 3 Experimental design layout and observed responses for trospium chloride ER tablets

From: Development, optimization and pharmacokinetic evaluation of biphasic extended-release osmotic drug delivery system of trospium chloride for promising application in treatment of overactive bladder

Batches

Factor A

Factor B

Factor C

Factor D

Response

Polyethylene oxide

Cellulose Acetate

Polyethylene glycol 6000

Orifice diameter

% drug release at 2 h (Acid stage)

% drug release at 5 h (Buffer stage)

% drug release at 11 h (Buffer stage)

% drug release at 20 h (Buffer stage)

mg

% ratio

% ratio

mm

%

%

%

%

TSP1

250

94

6

0.6

20

42

66

97

TSP2

250

94

6

0.6

18

43

65

96

TSP3

300

97

3

0.5

4

19

46

96

TSP4

200

91

3

0.5

10

25

65

100

TSP5

200

97

9

0.5

14

32

76

98

TSP6

200

91

9

0.7

42

65

82

100

TSP7

300

91

3

0.5

12

22

50

95

TSP8

300

91

9

0.5

14

52

70

94

TSP9

200

91

3

0.7

14

28

68

99

TSP10

300

97

9

0.5

12

32

58

95

TSP11

200

97

3

0.5

7

23

58

99

TSP12

300

97

3

0.7

5

17

43

92

TSP13

250

94

6

0.6

22

39

67

97

TSP14

300

97

9

0.7

15

36

61

93

TSP15

250

94

6

0.6

25

45

71

98

TSP16

300

91

3

0.7

10

27

50

92

TSP17

200

91

9

0.5

45

71

85

99

TSP18

300

91

9

0.7

19

43

65

96

TSP19

200

97

9

0.7

12

28

72

100

TSP20

200

97

3

0.7

8

21

60

100

  1. % Drug release values are expressed as mean where, n = 3